ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Grifols SA

Grifols SA (GRFS)

7,32
-0,02
(-0,27%)
Geschlossen 11 Juni 10:00PM
7,39
0,07
( 0,96% )
Vor Marktöffnung: 2:44PM

Grifols SA (GRFS) Aktie

Professionelle Tools für Privatanleger.

Premium

Wichtige Statistiken und Details

Current Price
7,39
( 0,96% )
Gebot
7,37
Fragen
7,42
Volumen
2.001
0,00 Tagesbereich 0,00
7,26 52-Wochen-Bereich 11,14
Marktkapitalisierung
Handelsende
7,32
Handelsbeginn
-
Letzter Handelszeitpunkt
13:47:00
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
US$ 2.784.015
Ausgegebene Aktien
680.575.312
Dividendenrendite (LTM)
(3,36%)
Kurs-Gewinn-Verhältnis
14,85
Gewinn pro Aktie (EPS)
-
Erlöse (LTM)
7,44B
Nettogewinn (LTM)
415M

Über Grifols SA

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company... Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain. Mehr anzeigen

Sektor
Healthcare
Branche
Pharmaceuticals
Website
Hauptsitz
Barcelona, Spain
Gegründet
2026
Grifols SA is listed in the Healthcare sector of the NASDAQ with ticker GRFS. The last closing price for Grifols was US$7,32. Over the last year, Grifols shares have traded in a share price range of US$ 7,26 to US$ 11,14.

Grifols currently has 680.575.312 shares in issue. The market capitalisation of Grifols is US$5,03 billion. Grifols has a price to earnings ratio (PE ratio) of 14.85.

GRFS Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.19-2.506596306077.587.737.266550537.392074DR
4-0.41-5.256410256417.88.2357.266194857.75245914DR
12-0.31-4.025974025977.78.837.267019677.97087989DR
26-1.56-17.43016759788.959.777.266387458.4367741DR
52-1.58-17.61426978828.9711.147.267097119.1051013DR
156-1.32-15.15499425958.7112.14995.300111099758.2213011DR
260-11.53-60.940803382718.9219.075.300110446218.95816473DR

GRFS - Frequently Asked Questions (FAQ)

What is the current Grifols SA share price?
The current share price of Grifols SA is US$ 7,39
How many Grifols SA shares are in issue?
Grifols SA has 680.575.312 shares in issue
What is the market cap of Grifols SA?
The market capitalisation of Grifols SA is USD 5,03B
What is the 1 year trading range for Grifols SA share price?
Grifols SA has traded in the range of US$ 7,26 to US$ 11,14 during the past year
What is the PE ratio of Grifols SA?
The price to earnings ratio of Grifols SA is 14,85
What is the cash to sales ratio of Grifols SA?
The cash to sales ratio of Grifols SA is 0,75
What is the registered address of Grifols SA?
The registered address for Grifols SA is Parque Empresarial Can Sant Joan, Barcelona, Catalonia, 08174
What is the Grifols SA website address?
The website address for Grifols SA is www.grifols.com
Which industry sector does Grifols SA operate in?
Grifols SA operates in the Pharmaceuticals sector

GRFS Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen